Insights

Rapid revenue growth AtaiBeckley has reported strong revenue growth with a 137% increase, signaling expanding market adoption and potential readiness for scale-up collaborations, licensing deals, or co-development partnerships with larger biopharma or specialty mental health companies.

Psychedelic pipeline The company is actively developing MDMA-based EMP-01 for social anxiety and intranasal formulations including 5-MeO-DMT variants for treatment-resistant depression, presenting multiple collaboration avenues in psychedelic-assisted therapies, formulation development, and regulatory strategy consulting.

Public market exposure Public listing since 2021 with notable stock performance and current market valuation around two billion dollars; leverage investor interest to pursue strategic partnerships, joint ventures, or advisory arrangements that align with ongoing clinical and commercialization milestones.

Clinical-stage focus As a clinical-stage biopharma targeting mental health, AtaiBeckley is positioned to explore research collaborations, access to specialty trials, patient cohort studies, and accelerated pathways with contract research organizations and academic partners.

Global treatment focus Intranasal and non-hallucinogenic research platforms alongside MDMA-based therapies suggest opportunities for international expansion, regulatory strategy support, and distribution partnerships in markets seeking innovative depression and anxiety treatments.

Similar companies to AtaiBeckley

AtaiBeckley Tech Stack

AtaiBeckley uses 8 technology products and services including Linkedin Insight Tag, Mimecast, React, and more. Explore AtaiBeckley's tech stack below.

Media & News

AtaiBeckley's Email Address Formats

AtaiBeckley uses at least 4 email formats:
AtaiBeckley Email FormatsExamplePercentage
First@atai.lifeJohn@atai.life
61%
First.Last@atai.lifeJohn.Doe@atai.life
32%
Last@atai.lifeDoe@atai.life
6%
First.L@atai.lifeJohn.D@atai.life
1%

Frequently Asked Questions

What is AtaiBeckley's stock symbol?

Minus sign iconPlus sign icon
AtaiBeckley is a publicly traded company; the company's stock symbol is ATAI.

What is AtaiBeckley's official website and social media links?

Minus sign iconPlus sign icon
AtaiBeckley's official website is ataibeckley.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does AtaiBeckley generate?

Minus sign iconPlus sign icon
As of October 2026, AtaiBeckley's annual revenue is estimated to be $25M - $50M.

What is AtaiBeckley's SIC code and NAICS code?

Minus sign iconPlus sign icon
AtaiBeckley's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AtaiBeckley have currently?

Minus sign iconPlus sign icon
As of October 2026, AtaiBeckley has approximately 106 employees across 3 continents, including North America, Europe and Asia. Key team members include Cao/Cfo/Vp/Controller: A. J., Chief Medical Officer: K. C. and Chief Research & Development Officer: R. C. Explore AtaiBeckley's employee directory with LeadIQ.

What industry does AtaiBeckley belong to?

Minus sign iconPlus sign icon
AtaiBeckley operates in the Biotechnology Research industry.

What technology does AtaiBeckley use?

Minus sign iconPlus sign icon
AtaiBeckley's tech stack includes Linkedin Insight Tag, Mimecast, React, Office 365, Vercel, Node.js, Smartsheet and Tailwind CSS.

What is AtaiBeckley's email format?

Minus sign iconPlus sign icon
AtaiBeckley's email format typically follows the pattern of First@atai.life. Find more AtaiBeckley email formats with LeadIQ.

How much funding has AtaiBeckley raised to date?

Minus sign iconPlus sign icon
As of October 2026, AtaiBeckley has raised $796M in funding. The last funding round occurred on Oct 16, 2025.

When was AtaiBeckley founded?

Minus sign iconPlus sign icon
AtaiBeckley was founded in 2018.
AtaiBeckley logo

AtaiBeckley

Biotechnology ResearchNew York, United States51-200 Employees

AtaiBeckley is a clinical-stage biotechnology company based in New York City that aims to advance mental health care by developing treatments that act quickly, last, and are convenient to use. Operating in the biotechnology research industry, it is positioned as a mid-sized firm focused on clinical development.

The company arose in 2025 from the combination of atai Life Sciences and Beckley Psytech. Its clinical-stage programs target mental health conditions with significant unmet needs, including treatment-resistant depression and social anxiety disorder. In recent months, the company has been active in industry collaborations and investor forums, and has engaged in partnerships intended to incorporate patient perspectives into research.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
ATAI
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
51-200

Section iconFunding & Financials

  • $796M

    AtaiBeckley has raised a total of $796M of funding over 15 rounds. Their latest funding round was raised on Oct 16, 2025 as a Post IPO Equity.

  • $25M - $50M

    AtaiBeckley's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.